# New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma

> **NCT00001335** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 90 (—)

## Conditions studied

- Ewing's Sarcoma
- Neuroblastoma
- Rhabdomyosarcoma

## Interventions

- **DRUG:** ADR-529
- **DRUG:** Topotecan
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT00001335
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1993-04
- **Primary completion:** —
- **Final completion:** 2002-01
- **Target enrollment:** 90 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001335, "New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00001335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*